SG11201903753QA - Zinc-?-pga compositions and methods for treating cancer - Google Patents

Zinc-?-pga compositions and methods for treating cancer

Info

Publication number
SG11201903753QA
SG11201903753QA SG11201903753QA SG11201903753QA SG11201903753QA SG 11201903753Q A SG11201903753Q A SG 11201903753QA SG 11201903753Q A SG11201903753Q A SG 11201903753QA SG 11201903753Q A SG11201903753Q A SG 11201903753QA SG 11201903753Q A SG11201903753Q A SG 11201903753QA
Authority
SG
Singapore
Prior art keywords
international
methods
tumors
compositions
pct
Prior art date
Application number
SG11201903753QA
Inventor
Jinhyuk Fred Chung
Original Assignee
Xylonix Ip Holdings Pte Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xylonix Ip Holdings Pte Ltd filed Critical Xylonix Ip Holdings Pte Ltd
Publication of SG11201903753QA publication Critical patent/SG11201903753QA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug, i.e. a dimer, oligomer or polymer of pharmacologically or therapeutically active compounds one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/645—Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) -., (19) World Intellectual Property 111111111111111111111111111111111111111111111111111111111111111111111111111110111111 Organization International Bureau (10) International Publication Number (43) International Publication Date ......'\"' WO 2018/084806 Al 11 May 2018 (11.05.2018) WIPO I PCT (51) International Patent Classification: HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, A61K 33/30 (2006.01) A61P 35/00 (2006.01) KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, A61K 47/64 (2017.01) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, (21) International Application Number: OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, PCT/SG2017/050545 SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (22) International Filing Date: (84) Designated States (unless otherwise indicated, for every 31 October 2017 (31.10.2017) kind of regional protection available): ARIPO (BW, GH, (25) Filing Language: English GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, (26) Publication Language: English UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, (30) Priority Data: EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, 10201609131Y 01 November 2016 (01.11.2016) SG MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, (71) Applicant: XYLONIX IP HOLDINGS PTE. LTD. KM, ML, MR, NE, SN, TD, TG). [SG/SG]; 10 Anson Road, #28-05A, International Plaza, Singapore 079903 (SG). Declarations under Rule 4.17: (72) Inventor: CHUNG, Jinhyuk Fred; 31 Poole Road, Singa- — of inventorship (Rule 4.17(iv)) pore 437522 (SG). Published: (74) Agent: PIZZEYS PTE LTD; 152 Beach Road, #04-08 — with international search report (Art. 21(3)) — Gateway East, Singapore 189721 (SG). = (81) Designated States (unless otherwise indicated, for every = _ kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, = DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, (54) Title: = ZINC-y-PGA COMPOSITIONS AND METHODS FOR TREATING CANCER (57) : The invention relates to pharmaceutical compositions FIGURE 2 comprising a zinc salt and a y-polyglutamic acid carrier, and, option- 2+ ally, an NF-kB inhibitor as a tumor-sensitizing agent, and methods for using such compositions to treat tumors in patients. Methods include NCI H460 lung cancer cell: administering a liquid dosage form or a solid dosage form of a thera- WT p53, no drug resistance traits lly effective amount of a Zn(ll) salt and a y-polyglutamic acid = = '\"\"''''' r= rN\"r\". ze o 7::t - ,,\",:= \"cr— :=1; carrier to a patient in need thereof. Methods of treating a broad spectrum of human tumors, including tumors with a drug-resistant phenotype, us- ing the disclosed compositions are Tumors that respond to the provided. = _ ..-. .,.g: ...... ,,,.:;:l .—., v „::: .... : u. !7! y _, pharmaceutical compositions disclosed herein include neuroendocrine = — 04 — ' = E M ES-SA Dx5 P-glycoprotein human sarcoma: (neuroblastoma), gastric, uterine, and lung tumors. expression, WT p53 w 'a 0 '' Ar= N \"'''' ,, N = \"\"\"' =:‘ 1 '''''' Ne 7::‘ ,- 1 g of , ,.,, Lin rolls E Li se .ells fatty _ Early sells Pa%psis 0- 0 L- C> GC T98G human neuroblastoma: Mul4drug Resistance Protein 1 (MRP1) expression, p53 defects 8/08 4 7— Llve apog LIve cells Earl Early 1 ApcgtI: ] r il. celk LEarl 14,1 , ' se is msls Il 0 Annexin V - FITC binding N C
SG11201903753QA 2016-11-01 2017-10-31 Zinc-?-pga compositions and methods for treating cancer SG11201903753QA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SG10201609131YA SG10201609131YA (en) 2016-11-01 2016-11-01 Zinc-pga compositions and methods for treating cancer
PCT/SG2017/050545 WO2018084806A1 (en) 2016-11-01 2017-10-31 ZINC-γ-PGA COMPOSITIONS AND METHODS FOR TREATING CANCER

Publications (1)

Publication Number Publication Date
SG11201903753QA true SG11201903753QA (en) 2019-05-30

Family

ID=60327362

Family Applications (3)

Application Number Title Priority Date Filing Date
SG10201609131YA SG10201609131YA (en) 2016-11-01 2016-11-01 Zinc-pga compositions and methods for treating cancer
SG11201903753QA SG11201903753QA (en) 2016-11-01 2017-10-31 Zinc-?-pga compositions and methods for treating cancer
SG10202013112YA SG10202013112YA (en) 2016-11-01 2017-10-31 Zinc-gamma-pga compositions and methods for treating cancer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SG10201609131YA SG10201609131YA (en) 2016-11-01 2016-11-01 Zinc-pga compositions and methods for treating cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG10202013112YA SG10202013112YA (en) 2016-11-01 2017-10-31 Zinc-gamma-pga compositions and methods for treating cancer

Country Status (10)

Country Link
US (1) US11944640B2 (en)
EP (1) EP3534914A1 (en)
JP (2) JP7083835B2 (en)
KR (1) KR102616690B1 (en)
CN (2) CN108014131B (en)
AU (2) AU2017354787B2 (en)
CA (1) CA3042383A1 (en)
MX (2) MX2019005104A (en)
SG (3) SG10201609131YA (en)
WO (1) WO2018084806A1 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
SG10201708886RA (en) * 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3810154A1 (en) * 2018-06-22 2021-04-28 Xylonix Pte. Ltd. Oncology treatments using zinc agents
KR102094182B1 (en) * 2018-06-28 2020-03-30 주식회사 알랙스탠드 water-soluble polyglutamic acid complex composition containing zinc
JP2024510327A (en) 2021-03-18 2024-03-06 ジロニックス・ピーティーイー．リミテッド Pharmaceutical polymer conjugates

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2897122A (en) 1956-10-04 1959-07-28 Frosst & Co Charles E Enteric coated product
JP2712583B2 (en) 1989-06-28 1998-02-16 味の素株式会社 Foods and drinks containing easily absorbable minerals
JP3551149B2 (en) 1992-03-24 2004-08-04 味の素株式会社 Easy-absorbable mineral-containing composition and food and drink containing it
EP0605757B1 (en) 1992-11-25 2001-08-16 Ajinomoto Co., Inc. Compositions and goods containing minerals and poly-gamma-glutamic acid
US5447732A (en) 1992-11-25 1995-09-05 Ajinomoto Co., Inc. High-absorption mineral-containing composition and foods
IL115156A (en) 1994-09-06 2000-07-16 Univ Georgia Pharmaceutical compositions for the treatment of cancer comprising 1-(2-hydroxymethyl-1,3-dioxolan-4-yl) cytosines
ITMI950515A0 (en) 1995-03-16 1995-03-16 Valpharma Sa GASTRO-RESISTANT FORMULATIONS CONTAINING ZINC
US6441025B2 (en) 1996-03-12 2002-08-27 Pg-Txl Company, L.P. Water soluble paclitaxel derivatives
JPH11313618A (en) 1998-05-06 1999-11-16 Yoshio Inoue Mineral (zinc) formulation for livestock gentle to stomach and its production
CA2395191A1 (en) 1999-12-23 2001-06-28 Tedman Ehlers Chalcone and its analogs as agents for the inhibition of angiogenesis and related disease states
US20020061599A1 (en) 1999-12-30 2002-05-23 Elling Christian E. Method of identifying ligands of biological target molecules
AU2003232884A1 (en) 2002-01-25 2003-09-02 Emory University Solenopsin a, b and analogs as novel angiogenesis inhibitors
WO2004080210A1 (en) 2003-03-14 2004-09-23 Boehringer Ingelheim Danmark A/S Compositions of dietary metals for support of the physiological intestinal development and prevention of diarrhoea
KR100498812B1 (en) 2003-07-10 2005-07-01 주식회사 바이오리더스 Composition for promoting an absorption of mineral in body comprising poly-gamma-glutamic acid having ultla high molecular weight
JP4457641B2 (en) 2003-11-10 2010-04-28 味の素株式会社 Gelatin capsule
JP5162812B2 (en) 2004-07-08 2013-03-13 大正製薬株式会社 Zinc-containing composition for oral administration
CN103735560A (en) 2005-06-07 2014-04-23 耶鲁大学 Methods of treating cancer and other conditions or disease states using lfmau and ldt
CA2612979A1 (en) * 2005-06-10 2006-12-21 Bipar Sciences, Inc. Parp modulators and treatment of cancer
JPWO2007043606A1 (en) * 2005-10-12 2009-04-16 株式会社ジェノラックＢｌ Antidiabetic drug comprising an anionic polyamino acid / metal complex
WO2007109290A2 (en) 2006-03-20 2007-09-27 Pharmacyclics, Inc. Water-soluble zinc ionophores, zinc chelators, and/or zinc complexes and use for treating cancer
CN101674852A (en) 2007-04-10 2010-03-17 日东电工株式会社 Multi-functional polyglutamate drug carriers
EP2155253A2 (en) 2007-05-09 2010-02-24 Nitto Denko Corporation Polyglutamate conjugates and polyglutamate-amino acid conjugates having a plurality of drugs
AU2008251836A1 (en) 2007-05-09 2008-11-20 Salutria Pharmaceuticals, Llc Spiro compounds for treatment of inflammatory disorders
AU2009344184B2 (en) 2009-04-10 2016-05-12 Cypress Pharmaceuticals, Inc. Phosphate-binding magnesium salts and uses thereof
JO3635B1 (en) 2009-05-18 2020-08-27 Millennium Pharm Inc Solid pharmaceutical compositions and processes for their production
CN101716180B (en) 2009-11-06 2013-04-24 广西强寿药业集团有限公司 Combined medicament for supplementing zinc and calcium and preparation method thereof
US20110117210A1 (en) 2009-11-17 2011-05-19 Andrey Ugolkov Therapeutic treatment of human cancers using simple salts of zinc
US9211258B2 (en) 2010-03-10 2015-12-15 Lupin Limited Rifaximin ready-to-use suspension
ES2627820T3 (en) 2011-09-13 2017-07-31 Pharmacyclics, Inc. Histone deacetylase inhibitor formulations in combination with bendamustine and uses thereof
JP6121556B2 (en) 2012-11-21 2017-04-26 ケイビーエス リサーチ、 エルエルシー Herbal supplements and methods of their use
TWI660748B (en) 2013-03-01 2019-06-01 日商大塚製藥股份有限公司 Suspension for oral administration comprising amorphous tolvaptan
WO2014155142A1 (en) * 2013-03-28 2014-10-02 Bbs Nanotechnology Ltd. Stable nanocomposition comprising doxorubicin, process for the preparation thereof, its use and pharmaceutical compositions containing it
JP2016516781A (en) 2013-04-12 2016-06-09 ネッド バイオシステムズ， インコーポレイテッド Cancer treatment
JP6262334B2 (en) 2013-04-26 2018-01-17 日東電工株式会社 Large scale method for producing poly (glutamyl-glutamate) conjugates
US10398682B2 (en) 2013-07-15 2019-09-03 The Board Of Regents Of The University Of Texas System Methods and compositions to prevent or treat bacterial infections
JP2016069303A (en) 2014-09-29 2016-05-09 タカラバイオ株式会社 Hair loss inhibiting composition containing fucoidan as active ingredient
EP3006045B3 (en) 2014-10-07 2021-03-17 Cyprumed GmbH Pharmaceutical formulations for the oral delivery of peptide or protein drugs
AU2015330937B2 (en) 2014-10-08 2021-07-15 Theriva Biologics, Inc. Beta-lactamase formulations and uses thereof
US20160122739A1 (en) 2014-10-31 2016-05-05 Wisconsin Alumni Research Foundation Factor ix variants and methods of use therefor
WO2016088816A1 (en) 2014-12-03 2016-06-09 ノーベルファーマ株式会社 Tablet comprising zinc acetate hydrate and method for manufacturing same
EA201990530A1 (en) 2016-08-19 2019-07-31 БРУКЛИН ИММУНОТЕРАПЬЮТИКС ЭлЭлСи WAYS OF APPLICATION OF PD-1 / PD-L1 INHIBITORS AND / OR CTLA-4 INHIBITORS WITH A BIOLOGICAL PRODUCT CONTAINING SEVERAL CYTOKINE COMPONENTS FOR THE TREATMENT OF CANCER
SG10201609131YA (en) 2016-11-01 2018-06-28 Xylonix Ip Holdings Pte Ltd Zinc-pga compositions and methods for treating cancer
SG10201708886RA (en) 2017-10-30 2019-05-30 Xylonix Ip Holdings Pte Ltd α-PGA-ZINC COMPOSITIONS AND METHODS FOR TREATING CANCER
EP3810154A1 (en) 2018-06-22 2021-04-28 Xylonix Pte. Ltd. Oncology treatments using zinc agents

Also Published As

Publication number Publication date
JP7466822B2 (en) 2024-04-15
AU2023203220A1 (en) 2023-06-22
SG10201609131YA (en) 2018-06-28
SG10202013112YA (en) 2021-02-25
KR102616690B1 (en) 2023-12-21
US11944640B2 (en) 2024-04-02
JP2022116255A (en) 2022-08-09
EP3534914A1 (en) 2019-09-11
CN108014131A (en) 2018-05-11
CN116350658A (en) 2023-06-30
AU2017354787B2 (en) 2023-02-23
KR20190120159A (en) 2019-10-23
WO2018084806A1 (en) 2018-05-11
JP7083835B2 (en) 2022-06-13
AU2017354787A1 (en) 2019-05-16
MX2022011372A (en) 2022-10-10
US20190255104A1 (en) 2019-08-22
CA3042383A1 (en) 2018-05-11
CN108014131B (en) 2023-04-14
JP2019534330A (en) 2019-11-28
MX2019005104A (en) 2019-10-30

Similar Documents

Publication Publication Date Title
SG11201903753QA (en) Zinc-?-pga compositions and methods for treating cancer
SG11201805300QA (en) Heterocyclic compounds as immunomodulators
SG11201910085UA (en) Atropine pharmaceutical compositions
SG11201901126UA (en) Combination therapy for cancer
SG11201809299QA (en) Formulations of an lsd1 inhibitor
SG11201803920TA (en) Compounds and compositions useful for treating disorders related to ntrk
SG11201804152RA (en) Heterocyclic compounds as immunomodulators
SG11201804901WA (en) Compounds for the treatment of cancer and inflammatory disease
SG11201806515RA (en) Eribulin-based antibody-drug conjugates and methods of use
SG11201804161VA (en) Compositions comprising bacterial strains
SG11201807809XA (en) A transient commensal microorganism for improving gut health
SG11201810280YA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201901996UA (en) Formulations of ( r)-2-amino-3-phenylpropyl carbamate
SG11201810420YA (en) Antibodies to alpha-synuclein and uses thereof
SG11201808710UA (en) Novel immunogenic cd1d binding peptides
SG11201909303TA (en) Point of delivery cold slurry generation
SG11201907804QA (en) Pharmaceutical composition comprising selexipag
SG11201808222RA (en) Methods of treatment of cholestatic diseases
SG11201808566WA (en) Polymorphic form of n-{6-(2-hydroxypropan-2-yl)-2-[2-(methylsulphonyl)ethyl]-2h-indazol-5-yl}-6-(trifluoromethyl)pyridine-2-carboxamide
SG11201900228YA (en) Administration and dosage of diaminophenothiazines
SG11201809751XA (en) Egfr inhibitor compounds
SG11201900443VA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201806544XA (en) Compounds and methods of treating rna-mediated diseases
SG11201900551WA (en) Spiro-lactam nmda receptor modulators and uses thereof
SG11201900546UA (en) Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof